Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form
A reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed for simultaneous determination of triclabendazole (TCB) and ivermectin (IVM) in pharmaceutical dosage form. A mobile phase consisting of acetonitrile/water (50:50 v/v) with a flow rate of 1.5 mL/min was used for c...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Journal of Analytical Methods in Chemistry |
| Online Access: | http://dx.doi.org/10.1155/jamc/5522915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849714196368850944 |
|---|---|
| author | Taj Ur Rahman Ajmal Zaman Ali Bahadur Muhammad Aurang Zeb Wajiha Liaqat Eman Y. Santali Sarah Alharthi Ruwida M. K. Omar Saif A. Alharthy Ashraf Ali |
| author_facet | Taj Ur Rahman Ajmal Zaman Ali Bahadur Muhammad Aurang Zeb Wajiha Liaqat Eman Y. Santali Sarah Alharthi Ruwida M. K. Omar Saif A. Alharthy Ashraf Ali |
| author_sort | Taj Ur Rahman |
| collection | DOAJ |
| description | A reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed for simultaneous determination of triclabendazole (TCB) and ivermectin (IVM) in pharmaceutical dosage form. A mobile phase consisting of acetonitrile/water (50:50 v/v) with a flow rate of 1.5 mL/min was used for chromatographic separation of the mixture of TCB and IVM. The developed method was found to be linear with the correlation coefficient (r = 0.999) for TCB and IVM in the presence of suspension. The limit of quantitation (LOQ), robustness, specificity, accuracy, and precision were validated for the developed method. The peak areas of five replicates of the samples were recorded, and the acceptance rate of suspension recovery was 98%. The intraday accuracies for TCB and IVM were 98.71% and 100.79%, respectively, with a relative standard deviation (RSD) of 0.87%. The limits of detection (LOD) of TCB and IVM were 0.058 mg/mL and 0.112 μg/mL, respectively, while the LOQ of TCB and IVM were 0.178 μg/mL and 0.340 μg/mL, respectively. The method’s % RSD for intra- and interday precision was deemed satisfactory. The developed method could be utilized for the determination and measurement of TCB and IVM in other samples. |
| format | Article |
| id | doaj-art-ed48b0794e774a7a816cca73d62b1be3 |
| institution | DOAJ |
| issn | 2090-8873 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Analytical Methods in Chemistry |
| spelling | doaj-art-ed48b0794e774a7a816cca73d62b1be32025-08-20T03:13:45ZengWileyJournal of Analytical Methods in Chemistry2090-88732025-01-01202510.1155/jamc/5522915Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage FormTaj Ur Rahman0Ajmal Zaman1Ali Bahadur2Muhammad Aurang Zeb3Wajiha Liaqat4Eman Y. Santali5Sarah Alharthi6Ruwida M. K. Omar7Saif A. Alharthy8Ashraf Ali9Department of ChemistryDepartment of Transdisciplinary StudiesDepartment of ChemistryDepartment of ChemistryDepartment of ChemistryDepartment of Pharmaceutical ChemistryDepartment of ChemistryPharmaceutical Chemistry DepartmentDepartment of Medical Laboratory SciencesDepartment of ChemistryA reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed for simultaneous determination of triclabendazole (TCB) and ivermectin (IVM) in pharmaceutical dosage form. A mobile phase consisting of acetonitrile/water (50:50 v/v) with a flow rate of 1.5 mL/min was used for chromatographic separation of the mixture of TCB and IVM. The developed method was found to be linear with the correlation coefficient (r = 0.999) for TCB and IVM in the presence of suspension. The limit of quantitation (LOQ), robustness, specificity, accuracy, and precision were validated for the developed method. The peak areas of five replicates of the samples were recorded, and the acceptance rate of suspension recovery was 98%. The intraday accuracies for TCB and IVM were 98.71% and 100.79%, respectively, with a relative standard deviation (RSD) of 0.87%. The limits of detection (LOD) of TCB and IVM were 0.058 mg/mL and 0.112 μg/mL, respectively, while the LOQ of TCB and IVM were 0.178 μg/mL and 0.340 μg/mL, respectively. The method’s % RSD for intra- and interday precision was deemed satisfactory. The developed method could be utilized for the determination and measurement of TCB and IVM in other samples.http://dx.doi.org/10.1155/jamc/5522915 |
| spellingShingle | Taj Ur Rahman Ajmal Zaman Ali Bahadur Muhammad Aurang Zeb Wajiha Liaqat Eman Y. Santali Sarah Alharthi Ruwida M. K. Omar Saif A. Alharthy Ashraf Ali Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form Journal of Analytical Methods in Chemistry |
| title | Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form |
| title_full | Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form |
| title_fullStr | Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form |
| title_full_unstemmed | Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form |
| title_short | Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form |
| title_sort | development of rp hplc method for simultaneous determination of triclabendazole and ivermectin in pharmaceutical suspension dosage form |
| url | http://dx.doi.org/10.1155/jamc/5522915 |
| work_keys_str_mv | AT tajurrahman developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT ajmalzaman developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT alibahadur developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT muhammadaurangzeb developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT wajihaliaqat developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT emanysantali developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT sarahalharthi developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT ruwidamkomar developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT saifaalharthy developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform AT ashrafali developmentofrphplcmethodforsimultaneousdeterminationoftriclabendazoleandivermectininpharmaceuticalsuspensiondosageform |